Published on
May 23, 2024
In the media
Greywolf Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders
About Greywolf Therapeutics
Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases.
Greywolf is headquartered in Oxford, UK.
More information: Website | LinkedIn
Media enquiries
Patrick White, Head of Communications
